How EU MDR Triggers REACH Obligations for Device Manufacturers

## How EU MDR Triggers REACH Obligations for Device Manufacturers For non-EU medical device manufacturers placing products on the European market, compliance with the EU Medical Device Regulation (MDR - Regulation (EU) 2017/745) is the primary focus. However, the MDR’s own requirements for material and substance safety can directly trigger significant obligations under a separate, complex regulation: REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals - Regulation (EC) No 1907/2006). This intersection means that understanding the chemical composition of a device is no longer just a quality or biocompatibility concern; it is a critical regulatory gateway. When a non-EU manufacturer’s activities fall under the scope of REACH, they are legally required to appoint a REACH Only Representative (OR) to fulfill their obligations. An OR is a natural or legal person established physically within the European Union who assumes the responsibilities of an importer under REACH. Scoping this engagement is a crucial strategic step, as the complexity, service model, and resource requirements can vary dramatically based on a company's device portfolio and supply chain maturity. Understanding the key factors that drive this complexity allows manufacturers to forecast needs, budget appropriately, and select an OR partner aligned with their specific compliance strategy. ### Key Points * **MDR as a Trigger:** The EU MDR's General Safety and Performance Requirement (GSPR) 10.4 forces manufacturers to assess and justify the presence of certain hazardous substances, which in turn uncovers potential REACH obligations. * **SVHCs Drive Complexity:** The presence of Substances of Very High Concern (SVHCs) on the ECHA Candidate List above a concentration of 0.1% weight-by-weight (w/w) in any device component (article) is a primary driver of complex communication and notification duties, including submissions to the SCIP database. * **Tonnage is Foundational for Registration:** For substances intentionally or unintentionally released from devices, the total volume imported into the EU per year determines the need for formal registration with the European Chemicals Agency (ECHA). Obligations begin at one tonne per year. * **The OR is a Legal Role:** A REACH Only Representative is not merely a consultant; they are a legal entity within the EU that formally assumes the legal responsibilities and liabilities of the non-EU manufacturer under REACH. * **Data is Paramount:** The ability to scope an OR engagement effectively depends entirely on the quality and completeness of data, including a detailed bill of materials (BOM), supplier declarations on substance composition, and accurate import volume calculations. * **Service Models Vary Widely:** ORs offer different engagement models, from basic annual retainers for legal representation to comprehensive, activity-based fees for complex tasks like substance registration, SIEF negotiation, and ongoing supply chain monitoring. ### Understanding the MDR-REACH Intersection The link between EU MDR and REACH is formalized in GSPR 10.4 of Annex I of the MDR. This requirement mandates that devices be designed and manufactured to reduce risks posed by substances, particularly those that are carcinogenic, mutagenic, or toxic to reproduction (CMR) or have endocrine-disrupting (ED) properties. If such substances are present above 0.1% w/w, the manufacturer must provide a specific justification for their presence in the technical documentation, considering factors like the lack of alternatives and the risk-benefit profile. This requirement forces manufacturers to conduct a deep analysis of their device's material composition, which often uncovers obligations under REACH that may have been previously overlooked. For medical device manufacturers, REACH obligations are typically triggered in two primary ways: 1. **Substance Registration:** If a substance is intended to be released from the device during normal use (e.g., a drug in a drug-eluting stent, a coating that wears off) and the total amount of that substance imported into the EU across all devices exceeds one tonne per year, it must be registered with ECHA. 2. **SVHC Notification and Communication:** If any component of the device—defined as an "article" under REACH—contains an SVHC from the ECHA Candidate List at a concentration greater than 0.1% w/w, specific communication and notification duties apply, regardless of the total tonnage. ### Key Factors Influencing REACH OR Engagement Complexity The scope and cost of a REACH OR service are not one-size-fits-all. They are directly influenced by the specific characteristics of a manufacturer's product portfolio and supply chain. #### 1. Device Portfolio and Material Composition * **Substance Volume (Tonnage Bands):** For substances requiring registration, the primary cost driver is the annual import volume. REACH organizes data requirements into tonnage bands (e.g., 1-10 tonnes/year, 10-100 tonnes/year). As the tonnage band increases, the required data set for the registration dossier becomes significantly more extensive and expensive to acquire. * **Presence and Number of SVHCs:** This is the most common and complex trigger for medical device companies. Each unique SVHC present above the 0.1% w/w threshold creates a cascade of obligations that the OR must manage: * **Article 33 Communication:** The manufacturer has a legal duty to provide recipients of the article (e.g., distributors, hospitals) with sufficient information to allow safe use, including, as a minimum, the name of the SVHC. This information must also be provided to consumers within 45 days of a request. * **SCIP Notification:** Since January 2021, companies supplying articles containing SVHCs (>0.1% w/w) must notify this information to ECHA’s **S**ubstances of **C**oncern **I**n **P**roducts (SCIP) database. This involves creating a detailed dossier for each affected article, including identifiers, categorization, and safe use information. A portfolio with dozens of such articles requires substantial work. * **Portfolio Diversity:** A company with hundreds of different devices or components will have a much larger data management challenge than a company with a single, simple product. Each component must be assessed individually for its SVHC content. #### 2. Supply Chain Maturity and Data Availability The quality of data received from suppliers is a critical variable. An OR’s work is straightforward if a manufacturer can provide a complete BOM with all substances, CAS numbers, and precise concentrations. However, this is rarely the case. Common challenges include: * **Incomplete Data:** Suppliers may provide declarations that only confirm compliance without revealing the specific substances used. * **Reluctance to Share:** Many suppliers are hesitant to share proprietary formulation details. * **Multi-tiered Supply Chains:** Information gets lost or diluted as it passes through multiple tiers of suppliers and sub-suppliers. In these situations, the OR's role may expand to include a significant supplier outreach and data collection campaign, which adds considerable time and cost to the engagement. #### 3. The Role in Substance Information Exchange Forums (SIEFs) For substance registration, manufacturers cannot act alone. REACH mandates that all companies registering the same substance join a Substance Information Exchange Forum (SIEF). The SIEF’s purpose is to facilitate data sharing to avoid duplicate animal testing and reduce costs. The OR's role here is highly specialized and critical: * **Identifying and Joining the SIEF:** The OR must locate the correct SIEF for each substance. * **Negotiating Data Sharing:** The OR negotiates on the manufacturer's behalf with other SIEF members to gain access to the required toxicological and ecotoxicological data. * **Purchasing a Letter of Access (LoA):** Access to the data is typically granted by purchasing an LoA from the lead registrant of the SIEF. The cost of an LoA can range from a few thousand to hundreds of thousands of Euros, depending on the substance and the data's richness. ### Comparing REACH OR Service and Cost Models To accommodate these varying levels of complexity, REACH OR providers typically offer several service structures. #### Annual Retainer Model This model involves a fixed annual fee. * **What it Typically Covers:** Acting as the legal Only Representative in the EU, maintaining the ECHA REACH-IT account, and providing a basic level of regulatory monitoring and general advice. * **Best For:** Companies with no immediate registration or notification needs but who require a legal EU presence for potential future obligations or as a contractual requirement from their EU importers. #### Activity-Based / Project-Based Model This model bills for specific, discrete tasks. * **What it Typically Covers:** Fees are quoted for well-defined projects such as preparing and submitting a full substance registration dossier, managing a SCIP notification project for a product line, or conducting a supplier data collection campaign. * **Best For:** Manufacturers with a clear, immediate, and complex task, such as registering a high-tonnage substance. #### Hybrid Model This is the most common and flexible model. * **What it Typically Covers:** A modest annual retainer secures the OR’s legal appointment. All additional activities—SIEF negotiation, dossier work, SCIP submissions—are then quoted and billed separately as they arise. * **Best For:** The majority of medical device manufacturers. It provides a stable, compliant legal presence while offering the flexibility to scale support up or down as new products are introduced or as regulations (like the SVHC Candidate List) evolve. ### Preparing to Engage a REACH Only Representative: A Checklist To effectively scope the work and receive an accurate proposal from a potential OR, a manufacturer should undertake thorough preparation. #### Step 1: Internal Data Collection and Analysis - [ ] **Compile a Full Bill of Materials (BOM):** Create a detailed BOM for every device or system placed on the EU market, breaking it down to the lowest level of homogeneous components (e.g., a single O-ring, a specific screw, a housing). - [ ] **Identify All Chemical Substances:** For each component, identify every unique chemical substance and its CAS or EC number. - [ ] **Gather Weight and Concentration Data:** Determine the weight of each individual component and the concentration (% w/w) of each substance within it. - [ ] **Screen Against the SVHC Candidate List:** Systematically screen every substance in your portfolio against the latest ECHA Candidate List to identify any SVHCs present above the 0.1% w/w threshold. - [ ] **Calculate Annual Import Volumes:** For any substance requiring registration, calculate the total volume (in kilograms or tonnes) imported into the EU per year across all device models. #### Step 2: Supplier Communication and Documentation - [ ] **Request Full Material Disclosures (FMDs):** Reach out to all suppliers in your chain to request comprehensive material data. - [ ] **Obtain Formal REACH/SVHC Declarations:** If FMDs are not possible, obtain signed declarations from suppliers confirming the presence or absence of SVHCs in the components they provide. - [ ] **Utilize Non-Disclosure Agreements (NDAs):** Be prepared to use NDAs to facilitate the sharing of confidential formulation data from suppliers. #### Step 3: Scoping the Work with Potential ORs - [ ] **Provide a Substance Portfolio:** Present potential ORs with a clear list of substances that may require registration and their estimated annual tonnage bands. - [ ] **Highlight All Known SVHCs:** Clearly identify every device and component known to contain an SVHC above the 0.1% w/w threshold. - [ ] **Be Transparent About Data Gaps:** Explain where your data is strong and where it is weak. This helps the OR scope potential supplier outreach activities. - [ ] **Discuss Their Experience:** Ask about their specific experience with medical devices, SCIP notifications, and navigating SIEFs for complex substances. ## Finding and Comparing REACH Only Representative Providers Selecting the right REACH OR is a critical decision that impacts legal compliance, budget, and operational efficiency. When evaluating potential partners, manufacturers should look for providers with demonstrated experience at the intersection of medical devices and chemical regulations. Key qualifications include a deep understanding of the "article" definition as it applies to complex medical devices, proven success in SIEF negotiations, and efficient systems for managing SCIP notifications. It is also important to find a partner whose communication style and service model align with your company's needs. Comparing proposals from several qualified providers is the best way to ensure you find a cost-effective solution that covers your specific compliance risks. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/reach_only_rep) and request quotes for free. ### Key EU References - **Regulation (EC) No 1907/2006 (REACH):** The core EU regulation governing the registration, evaluation, authorisation, and restriction of chemical substances. - **Regulation (EU) 2017/745 (EU MDR):** The EU Medical Device Regulation, whose safety requirements often trigger REACH obligations. - **ECHA Guidance on requirements for substances in articles:** Official guidance from the European Chemicals Agency explaining the specific obligations related to substances contained in products. - **The SCIP Database:** The ECHA-managed database for information on Substances of Concern In articles as such or in complex objects (Products). This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*